Regimen produced durable response in indolent B-cell, mantle cell lymphomasHealioCombination therapy with lenalidomide plus low-dose dexamethasone and rituximab produced a high rate of durable responses in patients with rituximab-resistant, indolent B-…
|
Findings in Amino Acids Reported from Novartis Pharma
HispanicBusiness.com Our news journalists obtained a quote from the research from Novartis Pharma, “Here we report the characterization of a proposed biosimilar rituximab (GP2013) and originator rituximab. To compare GP2013 with originator rituximab using an extensive … |
OncLiveNovel B-Cell Receptor Signaling Inhibitors Show PromiseOncLiveMany of the patients in these studies were heavily pretreated, and many did not achieve objective responses, so the interest is in combining it with other active agents, such as benda…
|
Rituximab outperformed steroids in Graves’ ophthalmopathy
Healio SAN JUAN, Puerto Rico — Despite data presented earlier at the American Thyroid Association Annual Meeting showing that rituximab was not effective in treating Graves’ ophthalmopathy, another presenter here said that the drug does improve disease state … |
|
Roche Holding Ltd. (ADR) (RHHBY): Roche: Impact Of Rituxan Patent Expiration …
Seeking Alpha (click to enlarge) Rituxan (rituximab), MabThera in Europe, is a monoclonal antibody against B-lymphocytes CD20 surface protein used to treat lymphomas, leukemias, transplant rejection and rheumatoid arthritis. Novartis’ Sandoz generics division is on … |
Global and Chinese Monoclonal Antibody Industry Report, 2013GlobeNewswire (press release)In 2011, the sales of six monoclonal antibody agents as Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab …
PharmaStar |
Rituximab, flop nell’oftalmopatia di Graves
PharmaStar Il trattamento con l’anticorpo monoclonale anti-CD20 rituximab non si è rivelato utile nei pazienti con oftalmopatia di Graves (o esoftalmo basedowiano, una forma di esoftalmo che rappresenta una delle principali manifestazioni cliniche del morbo di … |
India.Com Health |
Rheumatoid Arthritis: Your guide to living with the disease
India.Com Health Biologics is the latest and most effective treatment available and it helps in normalising the life of a patient to a great extent. Some of the most common biologic medicines used today are Abatacept, Rituximab and Tocilizumab.’ According to some … |
|
GSK and Genmab file Arzerra for first-line use in US
PMLiVE … not responded to Genzyme’s Campath (alemtuzumab) or the chemotherapy fludarabine, but has brought in relatively modest sales in that setting thanks to robust competition from Roche’s Rituxan/ MabThera (rituximab), which has the same molecular target. |
CELL THERAPEUTICS INC : Cell Therapeutics Announces Results from …4-traders (press release)CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL….